Home LiteratureArticle Details
PMID: 20844748 Published · epublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Copy number analysis identifies novel interactions between genomic loci in ovarian cancer.

PloS one ·Vol. 5 ·No. 9 ·2010-09-10

Gorringe KL, George J, Anglesio MS, Ramakrishna M, Etemadmoghadam D, Cowin P, Sridhar A, Williams LH, Boyle SE, Yanaihara N, Okamoto A, Urashima M, Smyth GK, Campbell IG, Bowtell DD, Australian Ovarian Cancer Study

Abstract

Ovarian cancer is a heterogeneous disease displaying complex genomic alterations, and consequently, it has been difficult to determine the most relevant copy number alterations with the scale of studies to date. We obtained genome-wide copy number alteration (CNA) data from four different SNP array platforms, with a final data set of 398 ovarian tumours, mostly of the serous histological subtype. Frequent CNA aberrations targeted many thousands of genes. However, high-level amplicons and homozygous deletions enabled filtering of this list to the most relevant. The large data set enabled refinement of minimal regions and identification of rare amplicons such as at 1p34 and 20q11. We performed a novel co-occurrence analysis to assess cooperation and exclusivity of CNAs and analysed their relationship to patient outcome. Positive associations were identified between gains on 19 and 20q, gain of 20q and loss of X, and between several regions of loss, particularly 17q. We found weak correlations of CNA at genomic loci such as 19q12 with clinical outcome. We also assessed genomic instability measures and found a correlation of the number of higher amplitude gains with poorer overall survival. By assembling the largest collection of ovarian copy number data to date, we have been able to identify the most frequent aberrations and their interactions.

MeSH Terms
Adult Aged Chromosomes, Human/genetics Female Gene Dosage Gene Expression Regulation, Neoplastic Genomic Instability Humans Middle Aged Ovarian Neoplasms/genetics,pathology
Authors & Affiliations
16 authors, click to expand affiliations / ORCID
Gorringe Kylie L
Victorian Breast Cancer Research Consortium (VBCRC) Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, East Melbourne, Australia.
George Joshy
Anglesio Michael S
Ramakrishna Manasa
Etemadmoghadam Dariush
Cowin Prue
Sridhar Anita
Williams Louise H
Boyle Samantha E
Yanaihara Nozomu
Okamoto Aikou
Urashima Mitsuyoshi
Smyth Gordon K
Campbell Ian G
Bowtell David D L
Australian Ovarian Cancer Study
References (52)
52 references, click to expand
  1. BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells.
    Cancer Res. 2009 Oct 1;69(19):7577-86 PMID: 19738061
  2. Analysis of ovarian cancer cell lines using array-based comparative genomic hybridization.
    J Pathol. 2005 Jan;205(1):29-40 PMID: 15586366
  3. Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas.
    Gynecol Oncol. 2006 Feb;100(2):264-70 PMID: 16236351
  4. Ovarian carcinoma develops through multiple modes of chromosomal evolution.
    Cancer Res. 2003 Jun 15;63(12):3378-85 PMID: 12810674
  5. The consensus coding sequences of human breast and colorectal cancers.
    Science. 2006 Oct 13;314(5797):268-74 PMID: 16959974
  6. Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas.
    J Clin Oncol. 2007 Jun 1;25(16):2281-7 PMID: 17538174
  7. Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer.
    Clin Cancer Res. 2007 Oct 1;13(19):5745-55 PMID: 17908964
  8. Circular binary segmentation for the analysis of array-based DNA copy number data.
    Biostatistics. 2004 Oct;5(4):557-72 PMID: 15475419
  9. Identification of candidate growth promoting genes in ovarian cancer through integrated copy number and expression analysis.
    PLoS One. 2010 Apr 08;5(4):e9983 PMID: 20386695
  10. L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer.
    Nature. 1985 Nov 7-13;318(6041):69-73 PMID: 2997622
  11. A common genetic risk factor for colorectal and prostate cancer.
    Nat Genet. 2007 Aug;39(8):954-6 PMID: 17618282
  12. EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer.
    Cell. 2003 Nov 26;115(5):523-35 PMID: 14651845
  13. A PDGFRB-positive acute myeloid malignancy with a new t(5;12)(q33;p13.3) involving the ERC1 gene.
    Leukemia. 2008 Jan;22(1):216-8 PMID: 17690697
  14. Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing.
    Nat Genet. 2008 Jun;40(6):722-9 PMID: 18438408
  15. BRD4 bromodomain gene rearrangement in aggressive carcinoma with translocation t(15;19).
    Am J Pathol. 2001 Dec;159(6):1987-92 PMID: 11733348
  16. Neurofibromin 1 (NF1) defects are common in human ovarian serous carcinomas and co-occur with TP53 mutations.
    Neoplasia. 2008 Dec;10(12):1362-72, following 1372 PMID: 19048115
  17. Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer.
    Cancer Res. 1998 Mar 15;58(6):1130-4 PMID: 9515795
  18. High-resolution analysis of copy number alterations and associated expression changes in ovarian tumors.
    BMC Med Genomics. 2009 May 06;2:21 PMID: 19419571
  19. High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer.
    Genome Biol. 2007;8(10):R215 PMID: 17925008
  20. The gene encoding bone morphogenetic protein 8B is required for the initiation and maintenance of spermatogenesis in the mouse.
    Genes Dev. 1996 Jul 1;10(13):1657-69 PMID: 8682296
  21. High-resolution analysis of chromosomal breakpoints and genomic instability identifies PTPRD as a candidate tumor suppressor gene in neuroblastoma.
    Cancer Res. 2006 Apr 1;66(7):3673-80 PMID: 16585193
  22. A network model of a cooperative genetic landscape in brain tumors.
    JAMA. 2009 Jul 15;302(3):261-75 PMID: 19602686
  23. High resolution genomic analysis of sporadic breast cancer using array-based comparative genomic hybridization.
    Breast Cancer Res. 2005;7(6):R1186-98 PMID: 16457699
  24. Identification of novel gene amplifications in breast cancer and coexistence of gene amplification with an activating mutation of PIK3CA.
    Cancer Res. 2009 Sep 15;69(18):7357-65 PMID: 19706770
  25. Differentially regulated genes as putative targets of amplifications at 20q in ovarian cancers.
    Jpn J Cancer Res. 2002 Oct;93(10):1114-22 PMID: 12417041
  26. Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas.
    Clin Cancer Res. 2009 Feb 15;15(4):1417-27 PMID: 19193619
  27. Analysis of cytogenetic alterations in stage III serous ovarian adenocarcinoma reveals a heterogeneous group regarding survival, surgical outcome, and substage.
    Genes Chromosomes Cancer. 2004 Aug;40(4):342-8 PMID: 15188458
  28. Estimation and assessment of raw copy numbers at the single locus level.
    Bioinformatics. 2008 Mar 15;24(6):759-67 PMID: 18204055
  29. An ovarian tumor marker with homology to vaccinia virus contains an IgV-like region and multiple transmembrane domains.
    Cancer Res. 1992 Oct 1;52(19):5416-20 PMID: 1394148
  30. Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma.
    Hum Pathol. 2008 Aug;39(8):1239-51 PMID: 18602670
  31. Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups.
    Cancer Res. 1997 Oct 1;57(19):4360-7 PMID: 9331099
  32. Are there any more ovarian tumor suppressor genes? A new perspective using ultra high-resolution copy number and loss of heterozygosity analysis.
    Genes Chromosomes Cancer. 2009 Oct;48(10):931-42 PMID: 19603523
  33. Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer.
    Cancer Res. 2007 Apr 1;67(7):3074-84 PMID: 17409414
  34. High-resolution single nucleotide polymorphism array analysis of epithelial ovarian cancer reveals numerous microdeletions and amplifications.
    Clin Cancer Res. 2007 Aug 15;13(16):4731-9 PMID: 17699850
  35. Coexistence of copy number increases of c-Myc, ZNF217, CCND1, ErbB1 and ErbB2 in ovarian cancers.
    Onkologie. 2009 Jul;32(7):405-10 PMID: 19556818
  36. Parallel analysis of sporadic primary ovarian carcinomas by spectral karyotyping, comparative genomic hybridization, and expression microarrays.
    Cancer Res. 2002 Jun 15;62(12):3466-76 PMID: 12067990
  37. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status.
    Nature. 2002 Aug 29;418(6901):934 PMID: 12198537
  38. Progenetix.net: an online repository for molecular cytogenetic aberration data.
    Bioinformatics. 2001 Dec;17(12):1228-9 PMID: 11751233
  39. Comprehensive genomic characterization defines human glioblastoma genes and core pathways.
    Nature. 2008 Oct 23;455(7216):1061-8 PMID: 18772890
  40. Characterizing the cancer genome in lung adenocarcinoma.
    Nature. 2007 Dec 6;450(7171):893-8 PMID: 17982442
  41. High-resolution copy number arrays in cancer and the problem of normal genome copy number variation.
    Genes Chromosomes Cancer. 2008 Nov;47(11):933-8 PMID: 18663746
  42. Comparative genomic hybridization detects genetic imbalances in primary ovarian carcinomas as correlated with grade of differentiation.
    Cancer. 2001 Feb 1;91(3):534-40 PMID: 11169935
  43. Genomic and gene expression profiling of minute alterations of chromosome arm 1p in small-cell lung carcinoma cells.
    Br J Cancer. 2005 Apr 25;92(8):1553-60 PMID: 15785753
  44. A family of human microRNA genes from miniature inverted-repeat transposable elements.
    PLoS One. 2007 Feb 14;2(2):e203 PMID: 17301878
  45. Combined loss of Hey1 and HeyL causes congenital heart defects because of impaired epithelial to mesenchymal transition.
    Circ Res. 2007 Mar 30;100(6):856-63 PMID: 17303760
  46. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.
    Clin Cancer Res. 2008 Aug 15;14(16):5198-208 PMID: 18698038
  47. A faster circular binary segmentation algorithm for the analysis of array CGH data.
    Bioinformatics. 2007 Mar 15;23(6):657-63 PMID: 17234643
  48. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma.
    Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):20007-12 PMID: 18077431
  49. The genomic landscapes of human breast and colorectal cancers.
    Science. 2007 Nov 16;318(5853):1108-13 PMID: 17932254
  50. Amplicon profiles in ovarian serous carcinomas.
    Int J Cancer. 2007 Jun 15;120(12):2613-7 PMID: 17351921
  51. Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer.
    Int J Gynaecol Obstet. 2006 Nov;95 Suppl 1:S161-92 PMID: 17161157
  52. Novel patterns of genome rearrangement and their association with survival in breast cancer.
    Genome Res. 2006 Dec;16(12):1465-79 PMID: 17142309
Article Info
Journal
PloS one
Abbr.
PLoS One
ISSN
1932-6203
Published
2010-09-10
Epub
2010-00-10
Language
English
Region
United States
NLM ID
101285081
PMCID
PMC2937017
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com